Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer.
作者信息
Kargbo Robert B
机构信息
Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.
出版信息
ACS Med Chem Lett. 2020 Nov 20;11(12):2359-2360. doi: 10.1021/acsmedchemlett.0c00587. eCollection 2020 Dec 10.
Abstract
摘要
相似文献
1
Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer.用于癌症治疗的BCR-ABL融合蛋白降解方面的突破
ACS Med Chem Lett. 2020 Nov 20;11(12):2359-2360. doi: 10.1021/acsmedchemlett.0c00587. eCollection 2020 Dec 10.
2
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation.BCR-ABL蛋白降解的调控分子及相应过程
J Cancer. 2019 Jun 2;10(11):2488-2500. doi: 10.7150/jca.29528. eCollection 2019.
3
Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis.USP7 抑制诱导 BCR-ABL 降解和慢性髓性白血病细胞凋亡。
Cell Death Dis. 2021 May 7;12(5):456. doi: 10.1038/s41419-021-03732-6.
4
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.通过将ABL激酶抑制剂与IAP配体偶联来开发致癌性BCR-ABL蛋白的蛋白质降解诱导剂。
Cancer Sci. 2017 Aug;108(8):1657-1666. doi: 10.1111/cas.13284. Epub 2017 Jun 19.
5
Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.通过伊马替尼衍生物与cIAP1配体的共轭作用开发BCR-ABL降解诱导剂。
Bioorg Med Chem Lett. 2016 Oct 15;26(20):4865-4869. doi: 10.1016/j.bmcl.2016.09.041. Epub 2016 Sep 15.
6
Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.跨越abl/bcr和bcr/abl融合蛋白连接区域的肽段可结合常见的HLA I类分子。
Leukemia. 2000 Mar;14(3):419-26. doi: 10.1038/sj.leu.2401703.
7
Targeting of BCR-ABL: Lessons learned from BCR-ABL inhibition.
Cell Mol Biol (Noisy-le-grand). 2016 Oct 31;62(12):129-137. doi: 10.14715/cmb/2016.62.12.22.
8
BCR-ABL mutations in chronic myeloid leukemia.慢性髓性白血病中的 BCR-ABL 突变。
Hematol Oncol Clin North Am. 2011 Oct;25(5):997-1008, v-vi. doi: 10.1016/j.hoc.2011.09.005.
9
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.Bcr-Abl阳性急性白血病的新型靶向治疗：超越STI571
Oncogene. 2002 Dec 9;21(56):8584-90. doi: 10.1038/sj.onc.1206086.
10
Bag1 directly routes immature BCR-ABL for proteasomal degradation.Bag1 直接将未成熟的 BCR-ABL 导向蛋白酶体降解。
Blood. 2010 Nov 4;116(18):3582-92. doi: 10.1182/blood-2009-10-249623. Epub 2010 Jul 30.
引用本文的文献
1
Anticancer drugs: How to select small molecule combinations?抗癌药物：如何选择小分子组合？
Trends Pharmacol Sci. 2024 Jun;45(6):503-519. doi: 10.1016/j.tips.2024.04.012. Epub 2024 May 22.
2
Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.小分子抑制剂作为靶向致癌融合蛋白的治疗剂：现状和临床应用。
Molecules. 2023 Jun 9;28(12):4672. doi: 10.3390/molecules28124672.
本文引用的文献
1
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia.组蛋白去乙酰化酶抑制剂在慢性髓性白血病治疗效果中的表观遗传机制。
Biochem Pharmacol. 2020 Mar;173:113698. doi: 10.1016/j.bcp.2019.113698. Epub 2019 Nov 7.
2
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.慢性髓细胞白血病：耐药和持久的概念及其与 BCR-ABL1 转录本类型的关系。
Leukemia. 2019 Oct;33(10):2358-2364. doi: 10.1038/s41375-019-0562-1. Epub 2019 Aug 27.
3
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities.慢性粒细胞白血病，一个仍未解决的问题：陷阱与新的治疗可能性。
Drug Des Devel Ther. 2019 Mar 8;13:825-843. doi: 10.2147/DDDT.S191303. eCollection 2019.
4
BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?BCR/ABL1 样急性淋巴细胞白血病：如何诊断和治疗？
Cancer. 2019 Jan 15;125(2):194-204. doi: 10.1002/cncr.31848. Epub 2018 Dec 18.
5
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.Bcr-Abl 抑制剂的过去、现在和未来：从化学发展到临床疗效。
J Hematol Oncol. 2018 Jun 20;11(1):84. doi: 10.1186/s13045-018-0624-2.
Zotero 插件